Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone—a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar Rats

• Published in: Journal of molecular neuroscience 2018-11, Vol.66 (3), p.322-341
• Main Authors: Sumathi, Thangarajan, Vedagiri, Aishwariya, Ramachandran, Surekha, Purushothaman, Bhagyalakshmi
• Format: Article
• Language: English
• Subjects: Animals; Antioxidants; Biomedical and Life Sciences; Biomedicine; Brain - drug effects; Brain - metabolism; Carbonyl compounds; Carbonyls; Cell Biology; Choline; Edaravone - pharmacology; Edaravone - therapeutic use; Esterase; Free Radical Scavengers - pharmacology; Free Radical Scavengers - therapeutic use; Free radicals; Glutathione; Huntington Disease - drug therapy; Huntington Disease - etiology; Huntington's disease; Huntingtons disease; Lipid Peroxidation; Lipids; Male; Neostriatum; Neurochemistry; Neurology; Neuroprotection; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Neurosciences; Oxidative stress; Peroxidation; Proteins; Proteomics; Quinolinic acid; Quinolinic Acid - toxicity; Rats; Rats, Wistar; Rodents
• ISSN: 0895-8696; 1559-1166
• DOI: 10.1007/s12031-018-1168-1

In this study, we demonstrated for the first time the neuroprotective role of edaravone (Eda) (5 and 10 mg/kg b.w.), a potent free radical scavenger against the unilateral stereotaxic induction of quinolinic acid (QA) (300 nm/4 μl saline)-induced Huntington disease (HD)-like symptoms in behavioral, biochemical, and histological features in male Wistar rats striatum. QA induction, which mimics the early stage of HD, commonly causes oxidative stress to the cell and decreases the antioxidant defense mechanism by altering the level of lipid peroxidation (LPO), protein carbonyls, and nitrate concentration (NO) and the activities of glutathione family enzymes (GPx, GST, GR) and acetyl choline esterase concentration (AChE) which was found to be ameliorated by Eda treatment in both the tested doses 5 and 10 mg/kg b.w. in the significance of P <  0.05 and P <  0.01, respectively. Finally histopathological analysis by hematoxylin and eosin stain concluded the promising neurodefensive role of Eda in rat striatum at the dosage of 10 mg/kg b.w., with the decreased tissue damage and the number of damaged granular cells when compared to QA-induced groups.